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STRUCTURED ABSTRACT 
 
OBJECTIVES High platelet reactivity (HPR) was studied in patients presenting with ST segment elevation 
myocardial infarction (STEMI) due to stent thrombosis (ST) undergoing immediate percutaneous coronary 
intervention (PCI). 
 
BACKGROUND HPR on P2Y12 inhibitors (HPR-ADP) is frequently observed in stable patients who have 
suffered from ST. The HPR rates in patients presenting with ST for immediate PCI is unknown. 
 
METHODS Consecutive patients presenting with definite ST were included in a multicenter ST registry. 
Platelet reactivity was measured before immediate PCI with the VerifyNow P2Y12 or Aspirin assay. 
 
RESULTS Platelet reactivity was measured in 129 ST patients presenting with STEMI undergoing immediate 
PCI. HPR-ADP was observed in 76% of the patients, and HPR on aspirin (HPR-AA) in 13% of the patients. 
HPR rates were similar in patients who were on maintenance P2Y12 inhibitor and/or aspirin since stent 
placement vs. those without these medications. In addition, HPR-ADP was similar in patients loaded with a 
P2Y12 inhibitor shortly before immediate PCI vs. those who were not. In contrast, HPR-AA trended to be lower 
in patients loaded with aspirin as compared to those not loaded. 
 
CONCLUSIONS Approximately three out of four ST patients with STEMI undergoing immediate PCI had 
HPR-ADP, and 13% had HPR-AA. Whether patients were on maintenance antiplatelet therapy whilst 
developing ST or loaded with P2Y12 inhibitors shortly before undergoing immediate PCI had no influence on the 
HPR rates. This raises concerns that the majority of patients with ST have suboptimal platelet inhibition 
undergoing immediate PCI. 
 
KEYWORDS 
aspirin, platelet aggregation, platelet function tests, P2Y12 receptor antagonists, stent thrombosis 
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CONDENSED ABSTRACT 
 
Platelet reactivity was measured in 129 stent thrombosis patients presenting with ST segment elevation 
myocardial infarction for immediate PCI. The majority (76%) of the patients presented with high platelet 
reactivity (HPR) on P2Y12 inhibitors, and the minority (13%) with HPR on aspirin. These HPR rates were 
similar in patients who were on maintenance P2Y12 inhibitor or aspirin therapy and/or were loaded with P2Y12 
inhibitors shortly before immediate PCI. These patients might be at risk complications during or shortly after 
immediate PCI. The use of direct-acting, intravenously platelet inhibitors during PCI for stent thrombosis might 
be beneficial. 
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ABBREVIATIONS AND ACRONYMS 
 
ADP = adenosine diphosphate 
APT = antiplatelet therapy 
ARU = aspirin reaction unit 
HPR = high platelet reactivity 
HPR-AA = high platelet reactivity on aspirin 
HPR-ADP = high platelet reactivity on P2Y12 inhibitors 
PCI = percutaneous coronary intervention 
PRESTIGE = PREvention of late Stent Thrombosis by an Interdisciplinary Global European effort 
ST = stent thrombosis 
STEMI = ST segment elevation myocardial infarction 
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INTRODUCTION 
 
Prior studies have shown that patients with high platelet reactivity (HPR) on-treatment with the P2Y12 inhibitor 
clopidogrel after percutaneous coronary intervention (PCI) are at higher risk of death, myocardial infarction, and 
coronary stent thrombosis (ST) during follow-up (1). ST is a rare but severe complication of PCI. In a stable 
phase after ST, HPR on clopidogrel treatment has been reported in many patients (2,3), however nothing is 
known about the platelet reactivity and HPR rates in patients presenting with ST undergoing immediate PCI.  
It can be hypothesized that the HPR rates in ST patients presenting with ST segment elevation 
myocardial infarction (STEMI) might be similar as in patients with spontaneous STEMI, as around 80% of ST 
patients present with a myocardial infarction (4,5). In patients presenting with ST segment elevation myocardial 
infarction (STEMI), it is known that 63-93% have HPR measured at the time of immediate PCI after loading 
with P2Y12 inhibitors (clopidogrel, prasugrel, or ticagrelor) (6-9), and HPR after intravenously administration of 
aspirin in patients presenting with STEMI was observed in 6% of the patients (10). A clear difference however is 
that part of the ST patients are on antiplatelet therapy (APT) whilst developing ST whereas spontaneous STEMI 
patients are not. We wonder therefore how maintenance APT whilst developing ST and loading with APT 
shortly before immediate PCI influence platelet reactivity and HPR rates in ST patients presenting with STEMI. 
Therefore, the goal of this observational platelet function study of the PREvention of late Stent 
Thrombosis by an Interdisciplinary Global European effort (PRESTIGE) registry was to characterize platelet 
reactivity and HPR rates in ST patients presenting with STEMI undergoing immediate PCI. Platelet reactivity 
was also assessed 1-3 days after ST.  
 
METHODS 
Patient population and study design 
The PRESTIGE consortium was formed to investigate multiple aspects of ST including the degree of platelet 
inhibition measured with standard platelet function tests at several time points (11). The PRESTIGE clinical 
work package registered consecutive study eligible patients presenting with definite ST. The timing of ST was 
defined as early ST, including acute (<24 hours after stent implantation) and subacute ST (1-30 days), late ST 
(>30-365 days), and very late ST (>1 year) (12). Patients were prospectively included in the registry using a 
centralized telephone registration system. Data were collected according to a standardized protocol and were 
entered in a central electronic database (Open Clinica, Leuven Coordinating Centre, Leuven, Belgium). Patient 
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management and choice of APT were at the discretion of the treating physician. All patients provided written 
informed consent. The study was approved by the local Ethical Committees in each of the recruiting centers and 
was conducted according to the principles of the Declaration of Helsinki. Funding for PRESTIGE was provided 
by the European Commission under the Seventh Frame Work Program (grant agreement number 260309). The 
participating European centers are listed in the Appendix. 
 
Blood sampling and platelet function tests 
Consecutive patients underwent platelet function testing in the centers equipped with the appropriate facilities. 
Blood samples were collected via the arterial sheet on presentation with ST in the catheterization laboratory 
immediately prior to the start of the PCI procedure after loading with APT, and at 1-3 days after ST via the 
antecubital vein. Blood samples were collected into 3.2% sodium citrate Vacuette® tubes (Greiner Bio-one, 
Frickenhausen, Germany) for testing with the VerifyNow® (Accriva Diagnostics, San Diego, CA, USA), and 
into hirudin blood tubes (Roche Diagnostics International Ltd., Switzerland) for testing with the Multiplate® 
analyzer (Roche Diagnostics International Ltd., Switzerland). Both tests were performed according to 
manufacturer's instructions. 
Platelet reactivity was measured using the assays available in each center; the VerifyNow P2Y12, 
VerifyNow Aspirin, or Multiplate adenosine diphosphate (ADP) assay. HPR-ADP was defined as >208 P2Y12 
Reaction Units by the VerifyNow P2Y12, and as >46 Units (1 Unit = 10 AU*min) by the Multiplate ADP assay. 
HPR-AA was defined as >550 Aspirin Reaction Units (ARU) by the VerifyNow Aspirin assay. Platelet function 
test results that fell below these cut-off values were considered as indicative of no HPR. Patients with platelet 
counts of <100*10^9/L or >600*10^9/L were excluded from the analysis. 
 
Statistical analysis 
Analyses were performed using IBM SPSS Statistics 22.0 (SPSS Inc., Chicago, IL, USA). Categorical data are 
expressed as frequencies (%) and continuous data as mean ± standard deviation. Baseline characteristics are 
presented for patients with acute, subacute, late, or very late ST. Differences in platelet reactivity and HPR rates 
were analyzed using Fisher’s exact test for categorical data, or Mann-Whitney U test for continuous data. 
Differences in platelet reactivity between assessment of the platelet inhibition at presentation with ST for 
immediate PCI and at 1-3 days after ST were analyzed using Wilcoxon signed rank test. All tests were two-tailed 
and a p value < 0.05 was considered statistically significant. 
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RESULTS 
Study population 
In total, 661 patients with definite ST were enrolled in the PRESTIGE registry. Platelet function testing was 
performed in a total of 193 patients presenting with ST. Of these, 147 patients presented with STEMI. Eighteen 
patients were excluded from the analysis because of abnormal platelet counts or because blood sampling was not 
performed before PCI. Platelet reactivity was therefore measured in 129 patients, and in 65 of these patients the 
measurements were repeated at 1-3 days after ST. Of the latter, platelet function data were excluded from the 
analysis in 9 patients because of administration of the glycoprotein IIb/IIIa-receptor antagonist abciximab during 
immediate PCI, Figure 1. 
Of the unselected 129 patients with platelet function testing at presentation with ST, 10 patients 
presented with acute ST, 37 with subacute ST, 10 with late ST, and 72 with very late ST. Baseline characteristics 
at the time of index PCI (PCI of stent placement) are shown in Table 1. At presentation, 40% of the patients 
with acute, 81% with subacute, 70% with late, and 8% with very late ST were on maintenance therapy with a 
P2Y12 inhibitor whilst developing ST. Sixty percent of the patients with acute, 65% with subacute, 90% with 
late, and 97% with very late ST were loaded with a P2Y12 inhibitor shortly before immediate PCI (Table 2).  
Baseline characteristics of ST patients presenting with STEMI with and without platelet function testing 
were comparable, except that patients with platelet function testing received a loading dose of clopidogrel at 
presentation for immediate PCI more often than patients without platelet function testing (33.6 vs. 24.7%, p = 
0.050; Online Table 1 and 2), which is probably due to the observational character of the study.  
 At presentation, HPR-ADP was observed in 62/82 (75.6%) and in 61/79 (77.2%) patients measured 
with VerifyNow P2Y12 and Multiplate ADP respectively. HPR-AA was observed in 10/76 (13.2%) patients 
measured with VerifyNow Aspirin. 
 
HPR in patients on maintenance APT at presentation with ST 
At presentation with ST for immediate PCI, 32/82 and 29/79 patients measured with VerifyNow P2Y12 and 
Multiplate ADP were on maintenance therapy with a P2Y12 inhibitor, and 63/76 patients were on maintenance 
aspirin. HPR-ADP rates were no different in patients who were on maintenance therapy with a P2Y12 inhibitor 
whilst developing ST than in those without this therapy (Figure 2A). The number of patients was too low to 
differentiate between maintenance therapy with the different P2Y12 inhibitors. HPR-AA was also similar in 
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patients who were on aspirin at presentation with ST compared to those who were not (Figure 2C). The majority 
of the patients who were not on maintenance therapy with a P2Y12 inhibitor presented with very late ST (80%).  
 
HPR in patients loaded with APT at presentation with ST 
At presentation with ST for immediate PCI, 64/82 and 62/79 patients measured with VerifyNow P2Y12 and 
Multiplate ADP were loaded with a P2Y12 inhibitor shortly before immediate PCI and blood sampling, and 
55/76 patients were loaded with aspirin. The HPR-ADP rates were similar in patients loaded with a P2Y12 
inhibitor shortly before undergoing immediate PCI for ST vs. to those not loaded (Figure 2B). No differences in 
HPR-ADP rates were observed in patients loaded with the different P2Y12 inhibitors. The HPR-AA rate was 
non-significantly lower in patients loaded with aspirin (Figure 2D). The actual platelet reactivity levels of 
patients loaded with aspirin were lower than in those who were not (loaded vs. not loaded: 442 ± 66 ARU vs. 
498 ± 108 ARU, p = 0.006).  
The mean time between loading of APT and blood sampling was 94 ± 123 minutes (n = 65) when 
loaded with a P2Y12 inhibitor, and 128 ± 146 minutes (n = 48) when loaded with aspirin. The loading time when 
loaded with P2Y12 inhibitors was significantly shorter in patients with HPR-ADP than in patients without HPR-
ADP (Table 3). 
 
HPR in patients 1-3 days after ST 
Platelet reactivity was measured in 56 patients at a mean of 1.3 ± 0.7 days after ST. In the sub-set of patients 
measured at both time points HPR-ADP decreased from 66.7% to 7.4% when measured with VerifyNow P2Y12 
(n = 27), and from 77.1% to 8.6% when measured with Multiplate ADP (n = 35). HPR-AA decreased from 
26.1% to 8.7% (n = 23). Changes in platelet reactivity for patients treated with clopidogrel (38%), prasugrel 
(41%), or ticagrelor (20%), and aspirin (98%) at 1-3 days after ST are presented in Figure 3. 
 
DISCUSSION 
The PRESTIGE consortium recruited a large and unique registry of patients with definite ST enabling for the 
first time assessment of platelet reactivity in ST patients presenting with STEMI undergoing immediate PCI. 
These patients were also assessed for platelet reactivity 1-3 days after ST. The main findings of this registry are 
the following: 1) HPR-ADP was observed in 76% and HPR-AA in 13% of the patients undergoing immediate 
PCI for ST; 2) maintenance APT at presentation with ST did not influence the HPR-ADP and HPR-AA rates; 3) 
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similarly, loading with a P2Y12 inhibitor at presentation with ST did not influence the HPR-ADP rates; however 
loading with aspirin did decrease platelet reactivity; and 4) HPR-ADP and HPR-AA rates were markedly lower 
1-3 days after ST. 
Thus HPR-ADP was observed in ~76% of the ST patients undergoing immediate PCI, which is 
comparable to the 63-93% HPR-ADP rate in patients presenting with spontaneous STEMI (6-9), who are the 
closest comparison to ST patients presenting with STEMI. Also, the ranges of HPR-ADP rate in ST patients with 
or without maintenance APT (69-86%) or loaded or not with APT (73-94%) are comparable with the HPR rate 
in patients presenting with spontaneous STEMI, although patients presenting with spontaneous STEMI are less 
often on maintenance APT than patients presenting with ST. The HPR-AA rate of 13% in this registry is 
somewhat higher than the HPR-AA rate of 6% (measured with light transmission aggregometry) observed in 
patients presenting with STEMI and iv. administration of aspirin (10). This difference might be explained by the 
fact that not all patients in our registry were loaded with intravenously aspirin. 
An interesting finding of our registry is that HPR-ADP rates at presentation with ST for immediate PCI 
were no different in patients with or without maintenance therapy with a P2Y12 inhibitor, suggesting that the 
antiplatelet effects of this maintenance therapy are, to a large extent, overcome by the occurrence of ST. Possible 
mechanisms may be an increased level of immature platelets and/or increased platelet turnover immediately 
prior to ST occurs, as has previously been suggested for patients presenting with spontaneous STEMI where an 
increased level of reticulated platelets and higher platelet turnover were associated with an insufficient response 
to APT (13-17). The included ST patients for these analyses presented with STEMI, which lends support for 
these presumed mechanisms. Likewise, maintenance therapy with aspirin did not lower the HPR-AA rate in 
patients presenting with ST. 
 Loading with aspirin did lower platelet reactivity in patients presenting with ST, and the HPR-AA rate 
seemed lower. In daily practice, aspirin is administrated intravenously in STEMI patients and can directly inhibit 
circulating platelets, including released reticulated platelets. The intravenously administration of aspirin might 
explain the low HPR-AA rates in patients presenting with ST compared to the high HPR-ADP rates. P2Y12 
inhibitors are orally administrated, also in acute settings, which results in a delayed onset of action of these drugs 
due to the slower rate of gastrointestinal uptake and to hemodynamic changes during STEMI (18,19). This may 
be exacerbated by the use of morphine, which lowers gastrointestinal uptake and is associated with higher 
platelet reactivity compared to patients without morphine administration (20,21). In addition, clopidogrel and 
prasugrel need conversion to the active metabolite before platelet reactivity can be inhibited. These mechanisms 
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probably largely explain the absence of differences in HPR-ADP rates in patients who did or did not receive a 
loading dose. However, since platelet response to P2Y12 inhibitors is a time-dependent phenomenon, and the 
timing of loading with P2Y12 inhibitors was not standardized in this registry, this observation should be 
interpreted with caution. An effect of this time-dependent phenomenon was observed in ST patients, where 
patients with a longer time interval between loading with a P2Y12 inhibitor and measurement were less likely to 
exhibit HPR-ADP. 
HPR on clopidogrel in a stable phase is often seen in patients with a history of ST (2,3). HPR rates on 
maintenance APT could therefore have contributed to developing ST in this registry. However, the HPR rates we 
observed are too high to account as sole cause for ST (HPR-ADP at presentation vs. at 1-3 days follow-up: 
~70% vs. ~8%). Thus we observed that platelet reactivity is not adequately inhibited in patients on maintenance 
APT and we consider it of great importance that also these patients should receive a loading dose of APT. HPR 
rates fell in the majority of the patients 1-3 days after ST suggesting that loading might have contributed to the 
observed decrease in platelet reactivity. Also, the use of a direct-acting, strong, intravenous P2Y12 inhibitor like 
cangrelor, or glycoprotein IIb/IIIa antagonists might be beneficial (21-23), as these patients might be at risk for 
complications, during or shortly after PCI(22-24). 
 
Study limitations 
This registry has several limitations. First, although the overall size of this registry of platelet function data is the 
largest at present, subgroup analysis was hindered by fragmentation into small numbers. This might explain the 
difference in HPR-AA rate at presentation with ST (13.2%) versus that in a sub-set of patients at presentation 
with ST who were also tested at 1-3 days (26.1%). Second, data on the time between loading of APT and blood 
sampling for platelet function testing were only available for half of the patients and were therefore less reliable 
to correlate to platelet reactivity levels. This might explain the absence of a difference in loading time between 
patients with or without HPR-AA while a difference was observed for patients loaded with P2Y12 inhibitors. 
Third, the majority of recruiting centers used either the VerifyNow or the Multiplate assay. While testing the 
same measure, these assays do not always provide the same level of sensitivity or specificity to detect HPR. Data 
for both platelet function tests were therefore presented separately. However, the concordance of HPR or no 
HPR between the VerifyNow P2Y12 and Multiplate ADP assays was high (85%) in the 34 patients measured 
with both assays at the time of presentation with ST. Fourth, data was not available on the administrated route 
(intravenously or orally) for aspirin. Fifth, platelet function testing was described but not mandated in the 
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PRESTIGE protocol, and platelet function testing was not feasible at all participating centers. Therefore, not 
every patient included in this registry was tested for platelet reactivity at presentation with ST, or at 1-3 days 
after ST. Nevertheless, even in the remaining small group of patients 1-3 days after ST, platelet reactivity levels 
1-3 days after ST were clearly lower. 
 
CONCLUSIONS 
HPR-ADP was observed in a high proportion (approximately 76%) and HPR-AA in the minority (13%) of the 
ST patients presenting with STEMI undergoing immediate PCI. Whether patients were on maintenance APT 
whilst developing ST or loaded with P2Y12 inhibitors shortly before undergoing immediate PCI had no influence 
on the HPR rates. This raises concerns that the majority of patients with ST have suboptimal platelet inhibition 
undergoing immediate PCI. 
 
PERSPECTIVES 
WHAT IS KNOWN? It is known that approximately 80% of the patients presenting with spontaneous STEMI 
have high platelet reactivity (HPR) at presentation for immediate PCI. A difference with stent thrombosis 
patients presenting with STEMI is that part of these patients are on maintenance antiplatelet therapy since stent 
placement.  
WHAT IS NEW? This study investigated for the first time the platelet reactivity in stent thrombosis patients 
presenting with STEMI for immediate PCI, and showed that HPR rates were comparable in patients on 
maintenance antiplatelet therapy or not, and similar in patients loaded with P2Y12 inhibitors or not. 
WHAT IS NEXT? Follow-up of patients treated with additional direct-acting, intravenously platelet inhibitor 
treatment during PCI could reveal whether this strategy will reduce the risk for (recurrent) thrombotic events.  
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FIGURE LEGENDS 
 
FIGURE 1 Flowchart of patient inclusion 
Flowchart of patient inclusion displays the number of patients analyzed for platelet reactivity and with which 
platelet function test at presentation with ST, and 1-3 days after ST. 
NSTEMI = non-ST segment elevation myocardial infarction; PCI = percutaneous coronary intervention; ST = 
stent thrombosis; STEMI = ST segment elevation myocardial infarction; UAP = unstable angina pectoris. 
 
FIGURE 2 High platelet reactivity rates in patients on maintenance or loaded with APT at presentation 
with ST for immediate PCI. 
High platelet reactivity rates are displayed for on maintenance or loaded with P2Y12 inhibitors or not, measured 
with VerifyNow P2Y12 or Multiplate ADP (A+B), and for on maintenance or loaded with aspirin measured with 
VerifyNow Aspirin (C+D). 
APT = antiplatelet therapy; HPR = high on-treatment platelet reactivity; HPR-AA = HPR on aspirin; HPR-ADP 
= HPR on P2Y12 inhibitors; LD = loading dose of a platelet inhibitor; MD = maintenance dose of a platelet 
inhibitor. 
 
FIGURE 3 Platelet reactivity at presentation with ST for immediate PCI and 1-3 days after ST.  
Sub-set of patients treated with antiplatelet therapy at 1-3 days after ST in whom platelet reactivity was also 
measured at presentation with ST for immediate PCI. Platelet reactivity was measured with VerifyNow P2Y12 or 
Multiplate ADP for clopidogrel-, prasugrel-, or ticagrelor-treated patients, and with VerifyNow Aspirin for 
aspirin-treated patients. Horizontal lines displays the cut-off value for high platelet reactivity of the used platelet 
function assay. 
ARU = aspirin reaction units; PCI = percutaneous coronary intervention; PRU = P2Y12 reactions units; U = 
units; ST = stent thrombosis. 
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Appendix 
General description of the PRESTIGE Consortium 
In 2010, a consortium of 14 European institutions joined forces to investigate stent thrombosis. The project 
consortium was named PRESTIGE—PREvention of late Stent Thrombosis by an Interdisciplinary Global 
European effort—and was coordinated by the Deutsches Herzzentrum München in Munich, Germany. It has run 
for 4 years, 2010–14. The project was funded by the European Commission under the Seventh Framework 
Programme (Grant Agreement No.: HEALTH-F2-2010-260309). Within the project, the scientists want to 
develop new concepts to identify and prevent ST. The strategy includes a basic scientific approach to decrypt the 
molecular and cellular mechanisms underlying ST, a bio-engineering approach focused on the development and 
testing of new intravascular imaging tools and stent materials to prevent stent thrombosis, plus a clinically-
orientated effort to better characterize the burden of ST across Europe. 
 
The consortium is led by Prof. Adnan Kastrati and Prof. Steffen Massberg and has participants from nine 
European Union countries, involving both academic centers and small- and medium-sized companies. 
 
Organization of the PRESTIGE Consortium 
 
Partners:  Deutsches Herzzentrum München (DHM); Azienda Ospedaliera Papa Giovanni XXIII 
(BER); Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w 
Krakowie (KRAK); St. Antonius Ziekenhuis Nieuwegein (NIE); University of Leicester 
(ULEIC); Universitäts-Herzzentrum Freiburg-Bad Krozingen GmbH (UHZ); Institut 
national de la santé et de la recherche médicale (INSERM); Rigas Tehniska Universitate 
(RTU); Kitozyme S.A. (KIZ); Helmholtz Zentrum München, Deutsches Forschungszentrum 
für Gesundheit und Umwelt GmbH (HMGU); Katholieke Universiteit Leuven 
(K.U.LEUVEN); Servicio Madrileño de Salud: Hospital Universitario Clinico San Carlos 
(SC) and Hospital Universitario de La Princesa (HULP); BIOTRONIK SE & Co. KG (BIO); 
neoplas GmbH (NEO). 
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Investigators: Belgium: Tom Adriaenssens (K.U.LEUVEN), Emanuele Barbato (OLV Hospital Aalst), 
Ann Belmans (K.U.LEUVEN), Ian Buysschaert (ZNA Middelheim), Mickaël Chausson 
(initially KIZ, now Synolyne Pharma), Dries De Cock (K.U.LEUVEN), Jo Dens (Oost-
Limburg Hospital, Genk), Walter Desmet (K.U.Leuven), Sandrine Gautier (initially KIZ, 
now Synolyne Pharma), Nick Hiltrop (K.U.LEUVEN), Katleen Vandenberghe 
(K.U.LEUVEN), Paul Vermeersch (ZNA Middelheim), Peter Sinnaeve (K.U.LEUVEN); 
Czech Republic: Ota Hlinomaz (St. Anne University Hospital, Brno); France: Helene 
Abergel (INSERM), Laurent Feldman (INSERM), Martine Jandrot-Perrus (INSERM), 
Didier Letourneur (INSERM), Pierre Mangin (INSERM); Véronique Olivier (INSERM), 
Caroline Roques (INSERM); Germany: Robert A. Byrne (DHM), Sue Chandraratne 
(initially DHM, now Klinikum der Universität München), Matthias Gratz (BIO), Elena 
Guerra (DHZ), Michael Joner (DHM), Adnan Kastrati (DHM), Elisabeth Kennerknecht 
(DHM), Ildiko Konrad (DHM), Tobias Koppara (DHM), Steffen Massberg (initially DHM, 
now Klinikum der Universität München), Franz-Josef Neumann (UHZ), Vasilis 
Ntziachristos (HMGU), Sheryl Opinaldo (initially DHM, now Klinikum der Universität 
München), Vanessa Philippi (initially DHM, now Klinikum der Universität München), Julia 
Riegger (initially DHM, now Klinikum der Universität München), Amir Rosenthal 
(HMGU), Alexander Rzany (BIO), Christian Schulz (initially DHM, now Klinikum der 
Universität München), Kristin Steigerwald (DHM), Tomohisa Tada (DHM), Anna Titova 
(initially DHM, now Klinikum der Universität München), Dietmar Trenk (UHZ), Christian 
Valina (UHZ), Andreas Vogelsang (NEO), Erion Xhepa (DHM); Italy: Chiara Bernelli 
(BER); Micol Coccato (BER), Giulio Guagliumi (BER), Kenichi Komukai (BER), Vasile 
Sirbu (BER); Latvia: Garry Kerch (RTU); The Netherlands: Giovanni Amoroso (Onze 
Lieve Vrouwe Gasthuis, Amsterdam), Jurriën ten Berg (NIE), Willem J.M. Dewilde 
(Amphia Ziekenhuis, Breda), Thea C. Godschalk (NIE), Antonius A.C.M. Heestermans 
(Medisch Centrum Alkmaar), Darshni A. Jhagroe (NIE), Joanne J. Wykrzykowska 
(Academisch Medisch Centrum, Amsterdam), Mark H.M. Winkens (TweeSteden 
ziekenhuis, Tilburg); Poland: Dariusz Dudek (KRAK), Łukasz Rzeszutko (KRAK), Roman 
Wojdyla (KRAK), Wojciech Zasada (KRAK); Spain: Fernando Alfonso (HULP, SC), 
Javier Cuesta (HULP), Miguel Medina (SC); United Kingdom: Colin Berry (University of 
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Glasgow; Golden Jubilee National Hospital, Glasgow), James Cotton (The Royal 
Wolverhampton Hospitals NHS Trust), Nick Curzen (University Hospital Southampton 
NHS Foundation Trust), Margaret McEntegart (Golden Jubilee National Hospital, 
Glasgow), Robert Gerber (East Sussex Healthcare NHS Trust), Anthony Gershlick 
(ULEIC), Alison H. Goodall (ULEIC), Simon Hetherington (Kettering General Hospital 
NHS Foundation Trust), Jonathan Hill (King's College Hospital NHS Foundation Trust), 
Damian Kelly (Derby Hospitals NHS Foundation Trust), Nikesh Malik (ULEIC), Keith 
Oldroyd (Golden Jubilee National Hospital, Glasgow), Helen Routledge (Worcestershire 
Acute Hospitals NHS Trust), Joanne Shannon (Frimley Health Foundation Trust), 
Venkatesan Suresh (Plymouth Hospitals NHS Trust), Azfar Zahman (Newcastle Upon Tyne 
Hospitals NHS Foundation Trust). 
 
Work Packages:  
Work package 1 (WP1): Gaining a better mechanistic understanding of the molecular and cellular 
events triggering late ST  
Leader: Martine Jandrot-Perrus (INSERM), Co-Leader: Steffen Massberg 
(initially DHM, now Klinikum der Universität München) 
Work package 2 (WP2): Developing and validating novel strategies to reduce late ST 
Leader: Michael Joner (DHM), Co-Leader: Didier Letourneur (INSERM) 
Work package 3(WP3): Developing and evaluating novel imaging technologies 
Leader: Giulio Guagliumi (BER), Co-Leader: Vasilis Ntziachristos (HMGU) 
Work package 4 (WP4): Performing a multi-stranded characterisation of patients with late ST 
Leader: Walter Desmet (K.U.LEUVEN), Co-Leader: Anthony Gershlick 
(ULEIC) 
 
Supplement material to: 
Observational study of platelet reactivity in patients presenting with STEMI due to coronary stent 
thrombosis undergoing primary PCI: results from the European PRESTIGE registry 
A report of the PREvention of late Stent Thrombosis by an Interdisciplinary Global European effort 
(PRESTIGE) consortium 
 
Running title: Platelet reactivity in patients presenting with ST 
 
Thea C. Godschalk, MSc,a Robert A. Byrne, MD, PhD,b,c Tom Adriaenssens, MD, PhD,d Nikesh Malik, MD,e 
Laurent J. Feldman, MD, PhD,f Giulio Guagliumi, MD,g Fernando Alfonso, MD, PhD,h Franz-Josef Neumann, 
MD, PhD,i Dietmar Trenk, PhD,i Michael Joner, MD, PhD,b Christian Schulz, MD, PhD,c,j Philippe G. Steg, 
MD, PhD,f,k Alison H. Goodall, PhD,e Roman Wojdyla, MD,l Dariusz Dudek, MD, PhD,m Joanna J. 
Wykrzykowska, MD, PhD,n Ota Hlinomaz, MD, PhD,o Azfar G Zaman, MD, PhD,p Nick Curzen, MD, PhD,q Jo 
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The PREvention of late Stent Thrombosis by an Interdisciplinary Global European effort (PRESTIGE) 
investigators 
 
a Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands; b Deutsches Herzzentrum 
München, Technische Universität München, Munich, Germany; c DZHK (German Centre for Cardiovascular 
Research), partner site Munich Heart Alliance, Munich, Germany; d Department of Cardiology, University 
Hospitals Leuven and Department of Cardiovascular Sciences, KU Leuven, Belgium; e Department of 
Cardiovascular Sciences, University of Leicester and NIHR Cardiovascular Biomedical Research Centre, 
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Hospital and Masaryk University, Brno, Czech Republic; p Freeman Hospital and Institute of Cellular Medicine, 
Newcastle University, Newcastle-upon-Tyne, UK; q University Hospital Southampton, Southampton, UK;  
r Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium 
 
  
ONLINE TABLE 1 Baseline characteristics of patients presenting with STEMI due to ST at the time of 
index PCI 
 Without Platelet 
Function Testing 
(n = 381) 
With Platelet 
Function Testing 
(n = 129) 
p Value 
Age, yrs 59 ± 13 61 ± 12 0.26 
Sex (male) 313 (82.2) 104 (80.6) 0.70 
Body mass index, kg/m2) 27.6 ± 4.4 27.7 ± 5.8 0.78 
Type of ST    
 Acute ST 38 (10.1) 10 (7.8) 0.40 
 Subacute ST 85 (22.5) 37 (28.7)  
 Late ST 23 (6.1) 10 (7.8)  
 Very late ST 232 (61.4) 72 (55.8)  
Cardiovascular risk factors    
 Active smoker 173 (49.3) 37 (30.1) <0.001 
 Diabetes 74 (19.6) 31 (24.0) 0.28 
 Hypertension 175 (47.7) 63 (50.0) 0.65 
 Hypercholesterolemia 318 (95.5) 121 (94.5) 0.66 
Prior myocardial infarction 102 (28.4) 33 (26.6) 0.70 
Prior CABG 17 (4.5) 6 (4.7) 0.93 
History of atrial fibrillation 18 (4.8) 9 (7.1) 0.31 
Renal failure (eGFR<30 ml/min/1.73m2) 8 (2.1) 2 (1.6) 0.70 
Malignancy 5 (1.3) 3 (2.4) 0.42 
Peripheral artery disease   23 (6.1) 9 (7.0) 0.74 
Stroke 21 (5.5) 8 (6.2) 0.78 
Thrombo-embolic events 30 (8.0) 10 (7.8) 0.94 
Heart failure (LVEF < 30%) 11 (3.0) 4 (3.2) 0.94 
Presentation for index PCI     
 SAP 95 (26.1) 29 (23.2) 0.090 
 UAP 41 (11.3) 23 (18.4)  
 NSTEMI 57 (15.7) 25 (20.0)  
 STEMI 171 (47.0) 48 (38.4)  
Target vessel for index PCI    
 RCA 141 (40.6) 49 (40.5) 0.92 
 LAD 161 (46.4) 59 (48.8)  
 Cx 41 (11.8) 12 (9.9)  
 Left main 4 (1.2) 1 (0.8)  
Stent type at index PCI    
 BMS 134 (36.7) 40 (33.1) 0.45 
 DES  223 (61.1) 80 (66.1)  
 BRS 8 (2.2) 1 (0.8)  
Values are n (%) or mean ± standard deviation.  
Baseline characteristics of patients presenting with STEMI due to ST undergoing immediate PCI without and 
with platelet function testing. Data was analyzed using the Chi-square test for categorical data, and the Student’s 
t-test for continuous data. 
BMS = bare metal stent; BRS = bioresorbable vascular scaffold; CABG = coronary artery bypass grafting; Cx = 
circumflex artery; DES = drug eluting stent; eGFR = estimated glomerular filtration rate; LAD = left anterior 
descending coronary artery; LVEF = left ventricular ejection fraction; NSTEMI = non-ST segment elevation 
myocardial infarction; PCI = percutaneous coronary intervention; RCA = right coronary artery; SAP = stable 
angina pectoris; ST = stent thrombosis; STEMI = ST segment elevation myocardial infarction; UAP = unstable 
angina pectoris. 
 
 
 
 
 
  
ONLINE TABLE 2 Baseline characteristics of patients presenting with STEMI due to ST at the time of 
presentation with ST for immediate PCI 
 Without Platelet 
Function Testing 
(n = 381) 
With Platelet 
Function Testing 
(n = 129) 
p Value 
Age, yrs 63 ± 12 64 ± 11 0.24 
Body mass index, kg/m2 27.7 ± 4.7 27.5 ± 5.4 0.84 
Active smoker 138 (37.5) 24 (19.0) <0.001 
Maintenance antiplatelet therapy    
 Dual antiplatelet therapy 146 (38.9) 42 (32.6) 0.20 
 Clopidogrel 113 (30.1) 33 (25.6) 0.33 
 Prasugrel 18 (4.8) 7 (5.4) 0.78 
 Ticagrelor 33 (8.8) 7 (5.4) 0.22 
 Aspirin 312 (83.0) 109 (84.5) 0.69 
Loaded with antiplatelet therapy    
 No P2Y12 inhibitor 87 (23.6) 24 (18.8) 0.26 
 Clopidogrel 91 (24.7) 43 (33.6) 0.050 
 Prasugrel 117 (31.7) 40 (31.3) 0.92 
 Ticagrelor 74 (20.1) 21 (16.4) 0.37 
 Aspirin 224 (61.4) 87 (68.5) 0.15 
Hemoglobin (mmol/L) 8.4 ± 1.2 8.4 ± 1.1 0.72 
Platelets (10^9/L) 266 ± 107 266 ± 87 0.99 
Values are n (%) or mean ± standard deviation.  
Baseline characteristics of patients presenting with STEMI due to ST undergoing immediate PCI without and 
with platelet function testing. Data was analyzed using the Chi-square test for categorical data, and the Student’s 
t-test for continuous data. 
PCI = percutaneous coronary intervention; ST = stent thrombosis. 
TABLE 1 Baseline characteristics at the time of index PCI 
Characteristic Acute ST 
(n = 10) 
Subacute ST 
(n = 37) 
Late ST 
(n = 10) 
Very late ST 
(n = 72) 
Age (years) 64 ± 10 68 ± 11 64 ± 11 57 ± 12 
Gender (male) 6 (60.0) 30 (81.1) 8 (80.0) 60 (80.6) 
Body mass index (kg/m2) 27.4 ± 5.5 27.7 ± 6.7 28.6 ± 10.1 27.6 ± 4.3 
Cardiovascular risk factors     
 Active smoker 3 (30.0) 6 (18.2) 2 (20.0) 26 (37.1) 
 Diabetes 4 (40.0) 13 (35.1) 4 (40.0) 10 (13.9) 
 Hypertension 3 (33.3) 22 (59.5) 5 (50.0) 33 (47.1) 
 Hypercholesterolemia 9 (90.0) 36 (97.3) 10 (100) 66 (93.0) 
Prior myocardial infarction 1 (11.1) 5 (13.9) 2 (20.0) 25 (36.2) 
Prior CABG 0 (0) 2 (5.4) 1 (10.0) 3 (4.2) 
History of atrium fibrillation 0 (0) 6 (16.7) 0 (0) 3 (4.3) 
Renal failure* 0 (0) 0 (0) 0 (0) 2 (2.8) 
Malignancy 0 (0) 2 (5.6) 0 (0) 1 (1.4) 
Peripheral artery diseases 1 (10) 4 (10.8) 2 (20.0) 2 (2.8) 
Stroke 0 (0) 3 (8.1) 0 (0) 5 (6.9) 
Thrombo-embolic events 0 (0) 3 (8.1) 1 (10.0) 6 (8.5) 
Heart failure (LVEF < 30%) 0 (0) 2 (5.6) 0 (0) 2 (2.9) 
Presentation for index PCI      
 SAP 1 (11.1) 12 (33.3) 1 (10.0) 15 (21.4) 
 UAP 0 (0.0) 3 (8.3) 2 (20.0) 18 (25.7) 
 NSTEMI 0 (0.0) 9 (25.0) 1 (10.0) 15 (21.4) 
 STEMI 8 (88.9) 12 (33.3) 6 (60.0) 22 (31.4) 
Target vessel for index PCI     
 RCA 8 (80.0) 10 (27.8) 6 (66.7) 25 (37.9) 
 LAD 2 (20.0) 20 (55.6) 3 (33.3) 34 (51.5) 
 Cx 0 (0) 5 (13.9) 0 (0) 7 (10.6) 
 Left main 0 (0) 1 (2.8) 0 (0) 0 (0) 
Stent type at index PCI     
 BMS 3 (30.0) 12 (32.4) 2 (20.0) 23 (35.9) 
 DES  7 (70.0) 24 (64.9) 8 (80.0) 41 (64.1) 
 BRS 0 (0) 1 (2.7) 0 (0) 0 (0) 
Values are n (%) or mean ± standard deviation.  
*) eGFR<30 ml/min/1.73m2 
BMS = bare metal stent; BRS = bioresorbable vascular scaffold; CABG = coronary artery bypass grafting; Cx = 
circumflex artery; DES = drug eluting stent; eGFR = estimated glomerular filtration rate; LAD = left anterior 
descending coronary artery; LVEF = left ventricular ejection fraction; NSTEMI = non-ST segment elevation 
myocardial infarction; PCI = percutaneous coronary intervention; RCA = right coronary artery; SAP = stable 
angina pectoris; ST = stent thrombosis; STEMI = ST segment elevation myocardial infarction; UAP = unstable 
angina pectoris. 
 
TABLE 2 Baseline characteristics at the time of presentation with ST for immediate PCI 
Characteristic Acute ST 
(n = 10) 
Subacute ST 
(n = 37) 
Late ST 
(n = 10) 
Very late ST 
(n = 72) 
Age (years) 64 ± 10 68 ± 11 64 ± 11 63 ± 12 
Body mass index (kg/m2) 28.1 ± 5.2 28.0 ± 6.6 27.9 ± 8.3 27.2 ± 4.3 
Active smoker 3 (30.0) 5 (14.3) 2 (20.0) 14 (19.7) 
Being on maintenance APT     
 Aspirin 5 (50.0) 32 (86.5) 9 (90.0) 63 (84.5) 
 Clopidogrel 3 (30.0) 22 (59.5) 3 (30.0) 5 (6.9) 
 Prasugrel 1 (10.0) 2 (5.4) 3 (30.0) 1 (1.4) 
 Ticagrelor 0 (0) 6 (16.2) 1 (10.0) 0 (0) 
Loaded with APT     
 Aspirin 7 (70.0) 14 (38.9) 6 (60.0) 60 (84.5) 
 Clopidogrel 4 (40.0) 7 (19.4) 4 (40.0) 28 (38.9) 
 Prasugrel 0 (0) 12 (33.3) 2 (20.0) 26 (36.1) 
 Ticagrelor 2 (20.0) 4 (11.1) 2 (20.0) 13 (18.1) 
Hemoglobin (mmol/L) 8.7 ± 1.2 8.0 ± 1.0 8.2 ± 0.6 8.6 ± 1.1 
Platelets (10^9/L) 233 ± 26 335 ± 111 290 ± 72 232 ± 54 
Values are n (%) or mean ± standard deviation.  
APT = antiplatelet therapy; PCI = percutaneous coronary intervention; ST = stent thrombosis. 
 
TABLE 3 Time between loading with antiplatelet therapy and blood sampling 
Platelet function assay HPR No HPR p Value 
VerifyNow P2Y12 55 ± 48 (n = 30) 127 ± 173 (n = 14) 0.059 
Multiplate ADP 89 ± 120 (n = 33) 200 ± 209 (n = 8) 0.026 
VerifyNow Aspirin 110 ± 45 (n = 4) 108 ± 134 (n = 35) 0.31 
Time is given in minutes, and displayed as mean ± standard deviation.  
HPR = high platelet reactivity. 
 



